Avalo Therapeutics AVTX
NASDAQ AVTX
$8.51 +1.35 (+18.85%)
At close: Nov 11, 2026 · 4:00 PM EST

Avalo Therapeutics (AVTX) Non Operating Interest Expenses (2014 - 2016)

Updated

Avalo Therapeutics' Non Operating Interest Expenses was $197,470 in Q3 2015, up 4.1% from $189,679 a year earlier.

Analysis

Avalo Therapeutics (AVTX) Non Operating Interest Expenses (2014 - 2016) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Interest Expenses (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn -
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 217.00 Mn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn -
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn -
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn -477.00 Mn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 653.00 Mn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn 269.00 Mn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn -
10 Avalo Therapeutics 386.09 Mn -587.48 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2016 34,489.00
Dec 31, 2015 39,534.00
Sep 30, 2015 197,470.00
Dec 31, 2014 -895,981.00
Sep 30, 2014 189,679.00
API Access

Avalo Therapeutics Non Operating Interest Expenses API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-operating-interest-expenses&ticker=AVTX&period=max&api_key=YOUR_API_KEY